<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version v40?><?ConverterInfo.XSLTName bmc2nlm.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neuroinflammation</journal-id><journal-title>Journal of Neuroinflammation</journal-title><issn pub-type="epub">1742-2094</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1742-2094-6-22</article-id><article-id pub-id-type="pmid">19698145</article-id><article-id pub-id-type="doi">10.1186/1742-2094-6-22</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Combarros</surname><given-names>Onofre</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>combarro@unican.es</email></contrib><contrib id="A2" contrib-type="author"><name><surname>van Duijn</surname><given-names>Cornelia M</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>c.vanduijn@erasmusmc.nl</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Hammond</surname><given-names>Naomi</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>nh4@sanger.ac.uk</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Belbin</surname><given-names>Olivia</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>Belbin.Olivia@mayo.edu</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Arias-V&#x000e1;squez</surname><given-names>Alejandro</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>a.ariasvasquez@umcn.nl</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Cortina-Borja</surname><given-names>Mario</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>m.cortina@ich.ucl.ac.uk</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Lehmann</surname><given-names>Michael G</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>mike@worldinneed.co.uk</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Aulchenko</surname><given-names>Yurii S</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>i.aoultchenko@erasmusmc.nl</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Schuur</surname><given-names>Maaike</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I7">7</xref><email>m.schuur@erasmusmc.nl</email></contrib><contrib id="A10" contrib-type="author"><name><surname>K&#x000f6;lsch</surname><given-names>Heike</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>heike.koelsch@iqwig.de</email></contrib><contrib id="A11" contrib-type="author"><name><surname>Heun</surname><given-names>Reinhard</given-names></name><xref ref-type="aff" rid="I8">8</xref><xref ref-type="aff" rid="I9">9</xref><email>heun@gmx.com</email></contrib><contrib id="A12" contrib-type="author"><name><surname>Wilcock</surname><given-names>Gordon K</given-names></name><xref ref-type="aff" rid="I10">10</xref><xref ref-type="aff" rid="I11">11</xref><email>Gordon.Wilcock@ndm.ox.ac.uk</email></contrib><contrib id="A13" contrib-type="author"><name><surname>Brown</surname><given-names>Kristelle</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>Kristelle.Brown@nottingham.ac.uk</email></contrib><contrib id="A14" contrib-type="author"><name><surname>Kehoe</surname><given-names>Patrick G</given-names></name><xref ref-type="aff" rid="I11">11</xref><email>Patrick.Kehoe@bristol.ac.uk</email></contrib><contrib id="A15" contrib-type="author"><name><surname>Harrison</surname><given-names>Rachel</given-names></name><xref ref-type="aff" rid="I11">11</xref><email>Rachel.Harrison@bristol.ac.uk</email></contrib><contrib id="A16" contrib-type="author"><name><surname>Coto</surname><given-names>Eliecer</given-names></name><xref ref-type="aff" rid="I12">12</xref><email>eliecer.coto@sespa.princast.es</email></contrib><contrib id="A17" contrib-type="author"><name><surname>Alvarez</surname><given-names>Victoria</given-names></name><xref ref-type="aff" rid="I12">12</xref><email>victoria.alvarez@sespa.princast.es</email></contrib><contrib id="A18" contrib-type="author"><name><surname>Deloukas</surname><given-names>Panos</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>panos@sanger.ac.uk</email></contrib><contrib id="A19" contrib-type="author"><name><surname>Mateo</surname><given-names>Ignacio</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mateonacho@hotmail.com</email></contrib><contrib id="A20" contrib-type="author"><name><surname>Gwilliam</surname><given-names>Rhian</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>rgl@sanger.ac.uk</email></contrib><contrib id="A21" contrib-type="author"><name><surname>Morgan</surname><given-names>Kevin</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>Kevin.Morgan@nottingham.ac.uk</email></contrib><contrib id="A22" contrib-type="author"><name><surname>Warden</surname><given-names>Donald R</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>donald.warden@dpag.ox.ac.uk</email></contrib><contrib id="A23" contrib-type="author"><name><surname>Smith</surname><given-names>A David</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>david.smith@pharm.ox.ac.uk</email></contrib><contrib id="A24" contrib-type="author"><name><surname>Lehmann</surname><given-names>Donald J</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>donald.lehmann@pharm.ox.ac.uk</email></contrib></contrib-group><aff id="I1"><label>1</label>Neurology Service and Centro de Investigaci&#x000f3;n Biom&#x000e9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Marqu&#x000e9;s de Valdecilla University Hospital (University of Cantabria), 39008 Santander, Spain</aff><aff id="I2"><label>2</label>Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands</aff><aff id="I3"><label>3</label>The Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK</aff><aff id="I4"><label>4</label>School of Molecular Medical Sciences, Institute of Genetics, University of Nottingham, Queens Medical Centre, Nottingham NG7 2UH, UK</aff><aff id="I5"><label>5</label>Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, 30 Guilford Street, London WC1N 1EH, UK</aff><aff id="I6"><label>6</label>Oxford Project to Investigate Memory and Ageing (OPTIMA), University Department of Physiology, Anatomy and Genetics, South Parks Road, Oxford OX1 3QX, UK</aff><aff id="I7"><label>7</label>Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands</aff><aff id="I8"><label>8</label>Department of Psychiatry, University of Bonn, Bonn, Germany</aff><aff id="I9"><label>9</label>Department of Psychiatry, Derby City General Hospital, Uttoxeter Road, Derby DE22 3NE, UK</aff><aff id="I10"><label>10</label>Nuffield Department of Medicine, University of Oxford, Level 4, John Radcliffe Hospital, Oxford OX3 9DU, UK</aff><aff id="I11"><label>11</label>Dementia Research Group, Institute of Clinical Neurosciences, University of Bristol, Frenchay Hospital, Frenchay, Bristol BS32 8BE, UK</aff><aff id="I12"><label>12</label>Gen&#x000e9;tica Molecular, Hospital Central de Asturias, Oviedo, Spain</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>23</day><month>8</month><year>2009</year></pub-date><volume>6</volume><fpage>22</fpage><lpage>22</lpage><ext-link ext-link-type="uri" xlink:href="http://www.jneuroinflammation.com/content/6/1/22"/><history><date date-type="received"><day>9</day><month>7</month><year>2009</year></date><date date-type="accepted"><day>23</day><month>8</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Combarros et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Combarros et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Combarros Onofre combarro@unican.es </dc:author><dc:title> Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>Journal of Neuroinflammation 6(1): 22-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1742-2094(2009)6:1&#x0003c;22&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1742-2094</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Chronic inflammation is a characteristic of Alzheimer's disease (AD). An interaction associated with the risk of AD has been reported between polymorphisms in the regulatory regions of the genes for the pro-inflammatory cytokine, interleukin-6 (IL-6, gene: <italic>IL6</italic>), and the anti-inflammatory cytokine, interleukin-10 (IL-10, gene: <italic>IL10</italic>).</p></sec><sec sec-type="methods"><title>Methods</title><p>We examined this interaction in the Epistasis Project, a collaboration of 7 AD research groups, contributing DNA samples from 1,757 cases of AD and 6,295 controls.</p></sec><sec><title>Results</title><p>We replicated the interaction. For <italic>IL6 </italic>rs2069837 AA &#x000d7; <italic>IL10 </italic>rs1800871 CC, the synergy factor (<italic>SF</italic>) was 1.63 (95% confidence interval: 1.10&#x02013;2.41, <italic>p </italic>= 0.01), controlling for centre, age, gender and apolipoprotein E &#x003b5;4 (<italic>APOE</italic>&#x003b5;4) genotype. Our results are consistent between North Europe (<italic>SF </italic>= 1.7, <italic>p </italic>= 0.03) and North Spain (<italic>SF </italic>= 2.0, <italic>p </italic>= 0.09). Further replication may require a meta-analysis. However, association due to linkage disequilibrium with other polymorphisms in the regulatory regions of these genes cannot be excluded.</p></sec><sec><title>Conclusion</title><p>We suggest that dysregulation of both IL-6 and IL-10 in some elderly people, due in part to genetic variations in the two genes, contributes to the development of AD. Thus, inflammation facilitates the onset of sporadic AD.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Alzheimer's disease (AD) is accompanied by a chronic inflammatory process, including activation of microglia and astrocytes that express pro-inflammatory cytokines [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. It is unclear to what extent this inflammation is a reaction to the pathology of AD, and to what extent it contributes to the onset or progression of the disease.</p><p>Two multi-functional cytokines, interleukin-6 (IL-6) and interleukin-10 (IL-10), may be relevant to this question. IL-6 is a potent pro-inflammatory cytokine [<xref ref-type="bibr" rid="B3">3</xref>], while IL-10 acts to limit inflammation in the brain [<xref ref-type="bibr" rid="B4">4</xref>]. Both are produced by activated microglia and astrocytes [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. Two single nucleotide polymorphisms (SNPs), rs1800795 (-174G/C) and rs1800896 (-1082G/A), in the regulatory regions of the genes, <italic>IL6 </italic>and <italic>IL10</italic>, respectively, have been widely studied. However, the ongoing AlzGene meta-analyses of the two SNPs [<xref ref-type="bibr" rid="B5">5</xref>]<ext-link ext-link-type="uri" xlink:href="http://www.alzforum.org/res/com/gen/alzgene/"/> are both currently negative (4 July 2009): pooled odds ratios for Caucasians in single-locus analyses of <italic>IL6</italic>-174C versus G alleles = 0.93 (95% confidence interval: 0.79&#x02013;1.08, 14 studies) and of <italic>IL10</italic>-1082G versus A alleles = 0.91 (0.74&#x02013;1.11, eight studies). Our own meta-analyses, both by allele and by genotype, confirmed these results and also indicated a high degree of heterogeneity among the studies (<italic>p </italic>&#x0003c; 0.05 in seven out of eight analyses, data not shown). Such inconsistencies may be due to study differences, e.g. in design or technical or analytical approach. However, the heterogeneity remained in six out of eight analyses after altogether four studies with controls in Hardy-Weinberg disequilibrium were removed. Alternatively, the heterogeneity may reflect true population differences, such as in interactions with other factors, including other genes. Such diverse results have been described as a marker of epistasis [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>], i.e. where the effect of one polymorphism depends on the genotype at another locus.</p><p>Infante et al (2004) [<xref ref-type="bibr" rid="B8">8</xref>] reported an interaction between <italic>IL6</italic>-174G/C and <italic>IL10</italic>-1082G/A associated with the risk of AD. We therefore set out to replicate this result in the Epistasis Project.</p><sec><title>The Epistasis Project</title><p>Sporadic Alzheimer's disease (AD) is a complex disease, with over 50% heritability [<xref ref-type="bibr" rid="B9">9</xref>]. This suggests that its study requires the investigation of interactions between risk factors, particularly genetic factors. The Epistasis Project studies such interactions, mainly those between distinct genetic loci, i.e. epistasis. The project is a collaboration of seven AD research groups: Bonn, Bristol, Nottingham, OPTIMA, Oviedo, Rotterdam and Santander (Table <xref ref-type="table" rid="T1">1</xref>). The project aims: first, to replicate genetic interactions that have been reported to affect the risk of sporadic AD; second, to explore other polymorphisms in the relevant genetic regions, ultimately to reveal the true risk loci. The overriding object is to gain insights into AD causality. However, interactions can only be reliably studied with sufficient statistical power and careful study design. The project therefore has these characteristics:-</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Sample-sets used in the Epistasis Project</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Group</td><td align="left">Geographical Region*</td><td align="left">Subjects<sup>&#x02020;</sup></td><td align="left">Numbers</td><td align="left">% women</td><td align="left"><italic>p </italic>(AD vs controls)</td><td align="left">Median age<sup>&#x02021; </sup>(interquartile range)</td><td align="left"><italic>p </italic>(AD vs controls)</td></tr></thead><tbody><tr><td align="left">Bonn</td><td align="left">Bonn and Mainz, Germany</td><td align="left">Clinical AD</td><td align="left">259</td><td align="left">61.4</td><td></td><td align="left">71.0 (65.1&#x02013;77.5)</td><td></td></tr><tr><td></td><td></td><td align="left">Screened controls</td><td align="left">232</td><td align="left">56.9</td><td align="left">0.31</td><td align="left">67.8 (64.4&#x02013;76.1)</td><td align="left">0.11</td></tr><tr><td align="left">Bristol</td><td align="left">South-West England</td><td align="left">Autopsy AD</td><td align="left">200</td><td align="left">45.0</td><td></td><td align="left">80.4 (75.6&#x02013;86.0)</td><td></td></tr><tr><td></td><td></td><td align="left">Autopsy controls</td><td align="left">57</td><td align="left">40.4</td><td align="left">0.55</td><td align="left">77.9 (72.8&#x02013;82.9)</td><td align="left">0.12</td></tr><tr><td align="left">Nottingham</td><td align="left">Cambridge, England</td><td align="left">Autopsy AD</td><td align="left">104</td><td align="left">48.1</td><td></td><td align="left">78.7 (70.8&#x02013;84.6)</td><td></td></tr><tr><td></td><td></td><td align="left">Autopsy controls</td><td align="left">107</td><td align="left">34.6</td><td align="left">0.051</td><td align="left">72.5 (65.6&#x02013;80.0)</td><td align="left">&#x0003c; 0.001</td></tr><tr><td align="left">OPTIMA</td><td align="left">Oxford, England</td><td align="left">Autopsy AD</td><td align="left">163</td><td align="left">54.6</td><td></td><td align="left">79.5 (72.4&#x02013;85.2)</td><td></td></tr><tr><td></td><td></td><td align="left">Clinical AD</td><td align="left">87</td><td align="left">54.0</td><td></td><td align="left">79.1 (73.4&#x02013;84.8)</td><td></td></tr><tr><td></td><td></td><td align="left">Screened controls</td><td align="left">261</td><td align="left">53.6</td><td align="left">0.93</td><td align="left">78.9 (72.9&#x02013;83.8)</td><td align="left">0.54</td></tr><tr><td align="left">Oviedo</td><td align="left">Asturias, Spain</td><td align="left">Clinical AD</td><td align="left">202</td><td align="left">69.8</td><td></td><td align="left">78.4 (74.8&#x02013;82.8)</td><td></td></tr><tr><td></td><td></td><td align="left">Screened controls</td><td align="left">131</td><td align="left">61.8</td><td align="left">0.15</td><td align="left">69.7 (63.5&#x02013;74.5)</td><td align="left">&#x0003c; 0.001</td></tr><tr><td align="left">Rotterdam</td><td align="left">Rotterdam (Ommord), the Netherlands</td><td align="left">Clinical AD</td><td align="left">391</td><td align="left">74.9</td><td></td><td align="left">86.6 (82.2&#x02013;91.6)</td><td></td></tr><tr><td></td><td></td><td align="left">Screened controls</td><td align="left">5,111</td><td align="left">57.7</td><td align="left">&#x0003c; 0.001</td><td align="left">76.9 (71.7&#x02013;83.0)</td><td align="left">&#x0003c; 0.001</td></tr><tr><td align="left">Santander</td><td align="left">Cantabria, Spain</td><td align="left">Clinical AD</td><td align="left">351</td><td align="left">65.0</td><td></td><td align="left">75.5 (70.8&#x02013;78.9)</td><td></td></tr><tr><td></td><td></td><td align="left">Screened controls</td><td align="left">396</td><td align="left">68.9</td><td align="left">0.27</td><td align="left">80.9 (74.7&#x02013;85.6)</td><td align="left">&#x0003c; 0.001</td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="left">Totals</td><td></td><td align="left">Total AD</td><td align="left">1,757</td><td align="left">62.4</td><td></td><td align="left">79.0 (73.0&#x02013;85.2)</td><td></td></tr><tr><td></td><td></td><td align="left">Total controls</td><td align="left">6,295</td><td align="left">57.7</td><td></td><td align="left">76.9 (71.3&#x02013;83.0)</td><td></td></tr></tbody></table><table-wrap-foot><p>AD = Alzheimer's disease</p><p>*from which the samples were drawn.</p><p><sup>&#x02020;</sup>Clinical AD cases were diagnosed as "probable AD" by NINCDS-ADRDA criteria [<xref ref-type="bibr" rid="B12">12</xref>]; autopsy AD cases were diagnosed as "definite" or "probable" by CERAD criteria [<xref ref-type="bibr" rid="B11">11</xref>]; screened controls were free of cognitive impairment; autopsy controls were free of pathology consistent with AD or other dementias; all controls were &#x02265; 60 years of age.</p><p><sup>&#x02021;</sup>Age at death or last examination.</p></table-wrap-foot></table-wrap><sec><title>1. Power</title><p>The project has 1,757 cases of AD and 6,295 elderly controls. These numbers give 99.9% power to detect an <italic>SF </italic>[<xref ref-type="bibr" rid="B10">10</xref>] of 2 between two polymorphisms, each with a minor allele frequency of 20%, when controlling for individual centres (2 below). They give 89.8% power or 48.6% power to detect <italic>SF</italic>s of 1.5 or 1.25, respectively. Quality control of genotyping reduces the numbers somewhat, depending on the polymorphism.</p></sec><sec><title>2. Selection of sample-sets</title><p>Only sample-sets drawn from narrow geographical regions with relatively homogeneous, Caucasian populations have been chosen, from seven AD research centres (Table <xref ref-type="table" rid="T1">1</xref> and Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>).</p></sec><sec><title>3. Sample characterisation</title><p>Cases of AD are either confirmed at autopsy as "definite" or "probable" by CERAD criteria [<xref ref-type="bibr" rid="B11">11</xref>], or clinically diagnosed as "probable AD" by NINCDS-ADRDA criteria [<xref ref-type="bibr" rid="B12">12</xref>]. Controls are either screened as free of cognitive impairment, or confirmed at autopsy as free of pathology consistent with AD or other dementias.</p></sec><sec><title>4. Matching of cases and controls</title><p>Only cases and controls drawn from the same region are compared, thus controlling for geographical differences, e.g. between North and South Europe.</p></sec><sec><title>5. Candidate interactions</title><p>Interactions are studied that have prior evidence of an association with AD and a plausible biological hypothesis. Interactions with age (&#x000b1; 75 years), gender and apolipoprotein E &#x003b5;4 (<italic>APOE</italic>&#x003b5;4) genotype are also examined.</p></sec><sec><title>6. Analytical methods</title><p>Logistic regression and <italic>SF </italic>[<xref ref-type="bibr" rid="B10">10</xref>] analyses are used. All analyses are controlled for age, gender and <italic>APOE</italic>&#x003b5;4 genotype. All pooled analyses are also controlled for centre. There is thus no question of controls from one centre (e.g., Rotterdam) being compared with AD cases from another region. Controlling for centre also reduces the relative influence of large subgroups, such as Rotterdam controls, in the pooled result. Where pooled analyses yield significant results, the seven individual centres are also examined for associations with AD, for heterogeneity, and for power to detect the interaction.</p><p>Table <xref ref-type="table" rid="T1">1</xref> gives the basic characteristics of the seven sample-sets. See Additional file <xref ref-type="supplementary-material" rid="S1">1</xref> for further information.</p><p>To select the interactions for study, a survey of over 100 published claims and suggestions of epistasis in sporadic AD was undertaken [<xref ref-type="bibr" rid="B13">13</xref>]. The interactions finally chosen are involved in various networks that are widely considered to contribute to the development of AD: lipid metabolism [<xref ref-type="bibr" rid="B14">14</xref>], &#x003b2;-amyloid metabolism [<xref ref-type="bibr" rid="B15">15</xref>], oxidative stress [<xref ref-type="bibr" rid="B16">16</xref>], inflammation [<xref ref-type="bibr" rid="B1">1</xref>], insulin metabolism [<xref ref-type="bibr" rid="B17">17</xref>] and homocysteine metabolism [<xref ref-type="bibr" rid="B18">18</xref>]. Positive results should therefore deliver insights into the causes of AD.</p></sec></sec></sec><sec sec-type="methods"><title>Methods</title><p>Basic information on the 1,757 cases of AD and the 6,295 controls from the seven centres is given above and in Table <xref ref-type="table" rid="T1">1</xref>, and fuller details are provided in Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>.</p><p>Genotyping for the six centres other than Rotterdam was performed at the Wellcome Trust Sanger Institute, using the iPLEX Gold assay (Sequenom Inc.). Whole genome amplified DNA was used for 82% of samples; genomic DNA was used for the 18% of samples that were not suitable for whole genome amplification. A Sequenom iPLEX, designed for quality control purposes, was used to assess genotype concordance between genomic and whole genome amplified DNA for 168 individuals. Assays for all SNPs were designed using the eXTEND suite and MassARRAY Assay Design software version 3.1 (Sequenom Inc.). Samples were amplified in multiplexed PCR reactions before allele specific extension. Allelic discrimination was obtained by analysis with a MassARRAY Analyzer Compact mass spectrometer. Genotypes were automatically assigned and manually confirmed using MassArray TyperAnalyzer software version 4.0 (Sequenom Inc.). Gender markers were included in all iPLEX assays as a quality control metric for confirmation of plate/sample identity. Genotyping of SNPs rs1800871, rs2069837 and rs3024505 was carried out using the KASPar technology by KBioscience <ext-link ext-link-type="uri" xlink:href="http://www.kbioscience.co.uk"/>.</p><p>Genotyping in the Rotterdam cohort was done on Version 3 Illumina-Infinium-II HumanHap550 SNP array (Illumina, San Diego, USA) and additionally, SNPs were imputed using MACH software <ext-link ext-link-type="uri" xlink:href="http://www.sph.umich.edu/csg/abecasis/MACH/"/> with HapMap CEU Release 22 as a reference [<xref ref-type="bibr" rid="B19">19</xref>]. The reliability of imputation was estimated for each imputed SNP with the ratio of expected and observed dosage variance (O/E ratio). Only samples with high-quality extracted DNA were genotyped; 5974 were available with good quality genotyping data; 5502 of these had reliable phenotypes. For the Epistasis Project, 52 genotyped SNPs and 116 imputed SNPs were selected.</p><p>We assessed associations with logistic regression models and <italic>SF </italic>analysis [<xref ref-type="bibr" rid="B10">10</xref>], controlling for age, gender, <italic>APOE</italic>&#x003b5;4 and study centre, using R Version 2.6.1 (R Foundation for Statistical Computing, Vienna, Austria). Heterogeneity between centres was controlled by fitting a fixed effect corresponding to contrasts between the baseline centre and the six other centres (having compared models with fixed- and random-effect terms in centre, goodness of fit was measured using Akaike's Information Criterion, which favoured using fixed effects only). Where the overall <italic>SF </italic>was significant at p &#x0003c; 0.05, the seven individual centres and the two geographical regions, North Europe and North Spain, were also examined. Power calculations were by <italic>SF </italic>analysis. Meta-analyses were performed using the random-effect method of DerSimonian and Laird [<xref ref-type="bibr" rid="B20">20</xref>] and the heterogeneity test of Armitage [<xref ref-type="bibr" rid="B21">21</xref>]. Comparisons of allelic frequencies between North Spain and North Europe were by Fisher's exact test. We compared the medians of the age distributions of AD and control groups using the Wilcoxon-Mann-Whitney test. Linkage disequilibrium data were estimated using the R genetics library <ext-link ext-link-type="uri" xlink:href="http://cran.r-project.org/web/packages/genetics/index.html"/>. All tests of significance were two-sided.</p></sec><sec><title>Results</title><p>We replicated the interaction reported by Infante et al (2004) [<xref ref-type="bibr" rid="B8">8</xref>] between <italic>IL6 </italic>rs1800795 (-174G/C) and <italic>IL10 </italic>rs1800896 (-1082G/A) (below). In the Rotterdam cohort, we examined altogether five <italic>IL6</italic>-related SNPs, rs1800797, rs1800795, rs2069837, rs2069840 and rs2069845, and four <italic>IL10</italic>-related SNPs, rs1800896, rs1800871, rs3024498 and rs3024505. In that preliminary study, we found that the strongest interactions were seen between <italic>IL6 </italic>rs2069837 (intron 2 A/G) and <italic>IL10 </italic>rs1800871 (-819C/T) and between <italic>IL6 </italic>rs2069837 and <italic>IL10 </italic>rs3024505 (3' C/T) (data not shown). We therefore studied the five SNPs shown in Table <xref ref-type="table" rid="T2">2</xref> in all seven sample-sets.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Studied SNPs</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Gene</td><td align="left">SNP</td><td></td><td align="left" colspan="3">Minor allele frequency in controls</td><td align="left" colspan="3">LD in controls</td></tr><tr><td></td><td></td><td></td><td colspan="6"><hr></hr></td></tr><tr><td></td><td></td><td></td><td align="left">North<break/>Europe</td><td align="left">North<break/>Spain</td><td align="left">Difference<break/>(<italic>p</italic>)</td><td align="left">With</td><td align="left">D'</td><td align="left">r<sup>2</sup></td></tr></thead><tbody><tr><td align="left"><italic>IL6</italic></td><td align="left">rs1800795</td><td align="left">-174G/C</td><td align="left">41.1% (C)</td><td align="left">32.8% (C)</td><td align="left">&#x0003c; 0.0001</td><td align="left">rs2069837</td><td align="left">0.998</td><td align="left">0.055</td></tr><tr><td></td><td align="left">rs2069837</td><td align="left">Intron 2 A/G</td><td align="left">7.3% (G)</td><td align="left">9.3% (G)</td><td align="left">0.03</td><td></td><td></td><td></td></tr><tr><td colspan="9"><hr></hr></td></tr><tr><td align="left"><italic>IL10</italic></td><td align="left">rs1800896</td><td align="left">-1082G/A</td><td align="left">50.7% (G)</td><td align="left">43.1% (G)</td><td align="left">&#x0003c; 0.0001</td><td align="left">rs1800871</td><td align="left">0.999</td><td align="left">0.296</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td align="left">rs3024505</td><td align="left">0.988</td><td align="left">0.191</td></tr><tr><td></td><td align="left">rs1800871</td><td align="left">-819C/T</td><td align="left">22.5% (T)</td><td align="left">26.7% (T)</td><td align="left">0.002</td><td align="left">rs3024505</td><td align="left">0.999</td><td align="left">0.058</td></tr><tr><td></td><td align="left">rs3024505</td><td align="left">3' C/T</td><td align="left">16.6% (T)</td><td align="left">14.2% (T)</td><td align="left">0.06</td><td></td><td></td><td></td></tr></tbody></table><table-wrap-foot><p>SNP = single nucleotide polymorphism; LD = linkage disequilibrium; D' = ratio of observed LD to maximum possible LD; r = correlation coefficient; <italic>IL6 </italic>and <italic>IL10 </italic>= the genes for interleukin-6 and interleukin-10, respectively.</p></table-wrap-foot></table-wrap><p>Hardy-Weinberg analysis was performed for the five SNPs of Table <xref ref-type="table" rid="T2">2</xref> in both cases and controls of the Rotterdam samples, genotyped by Rotterdam, and of the samples from the other six centres, genotyped by the Sanger Institute. As expected by chance, one of these 20 analyses resulted in disequilibrium: <italic>IL6</italic>-174G/C in AD cases of the six centres (<italic>p </italic>= 0.02). The two <italic>IL6 </italic>SNPs were in linkage disequilibrium (LD), as were the three <italic>IL10 </italic>SNPs (Table <xref ref-type="table" rid="T2">2</xref>). The allelic frequencies differed significantly between North Europe (Bonn, Bristol, Nottingham, OPTIMA and Rotterdam) and North Spain (Oviedo and Santander) in four out of the five SNPs (Table <xref ref-type="table" rid="T2">2</xref>).</p><p>We examined the potential associations with AD of the six interactions generated between the two <italic>IL6 </italic>SNPs and the three <italic>IL10 </italic>SNPs in our overall dataset (Table <xref ref-type="table" rid="T3">3</xref>), controlling for centre, age, gender and <italic>APOE</italic>&#x003b5;4 genotype (as in all association analyses). Three of the six interactions were associated with AD: <italic>SF p </italic>&#x0003c; 0.05. The first interaction shown in Table <xref ref-type="table" rid="T3">3</xref> is effectively identical to that reported by Infante et al 2004 [<xref ref-type="bibr" rid="B8">8</xref>]; we have merely reversed the first genotype, i.e. CC rather than GC + GG, to give an <italic>SF </italic>of 1.56, rather than its inverse, 0.64, for easier comparison with the other interactions. The two <italic>IL6 </italic>genotypes shown in Table <xref ref-type="table" rid="T3">3</xref> were in LD (<italic>p </italic>&#x0003c; 0.0001), as were the three <italic>IL10 </italic>genotypes (<italic>p </italic>&#x0003c; 0.0001). The interaction between <italic>IL6 </italic>intron 2 AA and <italic>IL10</italic>-819CC was slightly the strongest: <italic>SF </italic>= 1.63 (95% confidence interval = 1.10&#x02013;2.41, <italic>p </italic>= 0.01). All further analysis was therefore restricted to that interaction.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Potential interactions between <italic>IL6 </italic>SNPs and <italic>IL10 </italic>SNPs in the risk of AD</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Interaction</td><td></td><td align="left">Numbers</td><td></td><td align="left">Adjusted*<break/>synergy factor(95% CI, <italic>p</italic>)</td></tr><tr><td colspan="4"><hr></hr></td><td></td></tr><tr><td align="left"><italic>IL6</italic></td><td align="left">&#x000d7; <italic>IL10</italic></td><td align="left">Controls</td><td align="left">AD cases</td><td></td></tr></thead><tbody><tr><td align="left">rs1800795 CC</td><td align="left">&#x000d7; rs1800896 G+</td><td align="left">6153</td><td align="left">1557</td><td align="left"><bold>1.56 (1.02&#x02013;2.38, 0.04)</bold></td></tr><tr><td align="left">rs1800795 CC</td><td align="left">&#x000d7; rs1800871 CC</td><td align="left">6158</td><td align="left">1514</td><td align="left">1.25 (0.86&#x02013;1.80, 0.25)</td></tr><tr><td align="left">rs1800795 CC</td><td align="left">&#x000d7; rs3024505 T+</td><td align="left">6190</td><td align="left">1546</td><td align="left">1.11 (0.75&#x02013;1.64, 0.60)</td></tr><tr><td align="left">rs2069837 AA</td><td align="left">&#x000d7; rs1800896 G+</td><td align="left">6126</td><td align="left">1437</td><td align="left">1.37 (0.89&#x02013;2.11, 0.16)</td></tr><tr><td align="left">rs2069837 AA</td><td align="left">&#x000d7; rs1800871 CC</td><td align="left">6150</td><td align="left">1442</td><td align="left"><bold>1.63 (1.10&#x02013;2.41, 0.01)</bold></td></tr><tr><td align="left">rs2069837 AA</td><td align="left">&#x000d7; rs3024505 T+</td><td align="left">6172</td><td align="left">1429</td><td align="left"><bold>1.55 (1.02&#x02013;2.36, 0.04)</bold></td></tr></tbody></table><table-wrap-foot><p><italic>IL6 </italic>and <italic>IL10 </italic>= the genes for interleukin-6 and interleukin-10, respectively; SNPs = single nucleotide polymorphisms; AD = Alzheimer's disease; CI = confidence interval; G+ and T+ group the genotypes, GA+GG and CT+TT, respectively; <italic>APOE</italic>&#x003b5;4 = apolipoprotein E &#x003b5;4.</p><p>*All analyses controlled for centre, age, gender and <italic>APOE</italic>&#x003b5;4 genotype.</p></table-wrap-foot></table-wrap><p>Table <xref ref-type="table" rid="T4">4</xref> shows the effect of each of the two factors in that interaction on the association with AD of the other factor. The presence of <italic>IL10</italic>-819CC changed the association of <italic>IL6 </italic>intron 2 AA with AD from negative (odds ratio = 0.86, <italic>p </italic>= 0.30) to risk (odds ratio = 1.38, <italic>p </italic>= 0.02), while the presence of the latter removed the protective association of the former (odds ratio = 0.63, <italic>p </italic>= 0.01, changed to 1.08, <italic>p </italic>= 0.32).</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Odds ratios of Alzheimer's disease for two <italic>IL6 </italic>and <italic>IL10 </italic>SNPs, stratified by each other</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Odds ratio of AD for :-</td><td align="left">In the subset :-</td><td align="left">Numbers</td><td></td><td align="left">Adjusted* odds ratio of AD (95% CI, <italic>p</italic>)</td></tr><tr><td></td><td></td><td colspan="2"><hr></hr></td><td></td></tr><tr><td></td><td></td><td align="left">Controls</td><td align="left">AD cases</td><td></td></tr></thead><tbody><tr><td align="left"><italic>IL6</italic></td><td align="left"><italic>IL10</italic></td><td align="left">AA: 2158</td><td align="left">AA: 518</td><td align="left">0.86 (0.64&#x02013;1.15, 0.30)</td></tr><tr><td align="left">rs2069837</td><td align="left">rs1800871 T+</td><td align="left">G+: 348</td><td align="left">G+: 87</td><td></td></tr><tr><td align="left">AA vs G+</td><td align="left"><italic>IL10</italic></td><td align="left">AA: 3099</td><td align="left">AA: 724</td><td align="left"><bold>1.38 (1.06&#x02013;1.79, 0.02)</bold></td></tr><tr><td></td><td align="left">rs1800871 CC</td><td align="left">G+: 545</td><td align="left">G+: 113</td><td></td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><italic>IL10</italic></td><td align="left"><italic>IL6</italic></td><td align="left">CC: 545</td><td align="left">CC: 113</td><td align="left"><bold>0.63 (0.44&#x02013;0.91, 0.01)</bold></td></tr><tr><td align="left">rs1800871</td><td align="left">rs2069837 G+</td><td align="left">T+: 348</td><td align="left">T+: 87</td><td></td></tr><tr><td align="left">CC vs T+</td><td align="left"><italic>IL6</italic></td><td align="left">CC: 3099</td><td align="left">CC: 724</td><td align="left">1.08 (0.93&#x02013;1.25, 0.32)</td></tr><tr><td></td><td align="left">rs2069837 AA</td><td align="left">T+: 2158</td><td align="left">T+: 518</td><td></td></tr></tbody></table><table-wrap-foot><p><italic>IL6 </italic>and <italic>IL10 </italic>= the genes for interleukin-6 and interleukin-10, respectively; AD = Alzheimer's disease; CI = confidence interval; G+ and T+ group the genotypes, GA+GG and CT+TT, respectively; <italic>APOE</italic>&#x003b5;4 = apolipoprotein E &#x003b5;4.</p><p>*All analyses controlled for centre, age, gender and <italic>APOE</italic>&#x003b5;4 genotype.</p></table-wrap-foot></table-wrap><p>There was significant heterogeneity between the centres, and the interaction was only significant in one of the seven centres, Rotterdam, with an <italic>SF </italic>of 3.0 (95% confidence interval = 1.6&#x02013;5.8, <italic>p </italic>= 0.0007). But the power to detect an <italic>SF </italic>of 1.6 was low in each centre, ranging from below 10% to 40%. The results for North Europe (<italic>SF </italic>= 1.7, <italic>p </italic>= 0.03) and for North Spain (<italic>SF </italic>= 2.0, p = 0.09) were consistent (Table <xref ref-type="table" rid="T5">5</xref>).</p><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Interaction between <italic>IL6 </italic>rs2069837 AA vs G+ and <italic>IL10 </italic>rs1800871 CC vs T+, by region</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Region</td><td align="left">Power*</td><td align="left">Adjusted<sup>&#x02020; </sup>synergy factor (95% CI, <italic>p</italic>) in the risk of AD</td></tr></thead><tbody><tr><td align="left">North Europe<sup>&#x02021;</sup></td><td align="left">64%</td><td align="left"><bold>1.7 (1.05&#x02013;2.6, 0.03)</bold></td></tr><tr><td align="left">North Spain<sup>&#x02021;</sup></td><td align="left">37%</td><td align="left">2.0 (0.9&#x02013;4.4, 0.09)</td></tr><tr><td align="left">All</td><td align="left">76%</td><td align="left"><bold>1.6 (1.1&#x02013;2.4, 0.01)</bold></td></tr></tbody></table><table-wrap-foot><p><italic>IL6 </italic>and <italic>IL10 </italic>= the genes for interleukin-6 and interleukin-10, respectively; G+ and T+ group the genotypes, GA+GG and CT+TT, respectively; CI = confidence interval; AD = Alzheimer's disease; <italic>APOE</italic>&#x003b5;4 = apolipoprotein E &#x003b5;4.</p><p>*To detect a synergy factor of 1.6 (as in the overall dataset) at 0.05.</p><p><sup>&#x02020;</sup>All analyses controlled for centre, age, gender and <italic>APOE</italic>&#x003b5;4 genotype.</p><p><sup>&#x02021;</sup>North Europe = Rotterdam, Bonn, OPTIMA, Nottingham and Bristol; North Spain = Santander and Oviedo.</p></table-wrap-foot></table-wrap><p>Results were similar for men as for women (data not shown). The interaction was slightly stronger in older subjects: <italic>SF </italic>for &#x0003e; 75 years = 1.71 (1.05&#x02013;2.78, 0.03); <italic>SF </italic>for &#x0003c; 75 years = 1.27 (0.56&#x02013;2.87, 0.57). However, there was no 3-way interaction with age. Nor did we find a significant interaction with <italic>APOE</italic>&#x003b5;4.</p></sec><sec><title>Discussion</title><p>In our whole dataset of over 7,500 samples, we have replicated both the interaction reported by Infante et al 2004 [<xref ref-type="bibr" rid="B8">8</xref>] and also that found in our preliminary study in the Rotterdam dataset, between SNPs of <italic>IL6 </italic>and <italic>IL10 </italic>(Table <xref ref-type="table" rid="T3">3</xref>). Both interactions gave significant <italic>SF</italic>s of approximately 1.6. There was significant heterogeneity between centres, which was unsurprising since only two, Rotterdam and Santander, had &#x0003e; 20% power to detect these interactions. But the results for the two main regions, North Europe and North Spain, were consistent (Table <xref ref-type="table" rid="T5">5</xref>). We conclude that this is likely to be a true effect, but not a very strong one. As in any example of true epistasis, the presence or absence of one factor critically influenced the effect of the other (Table <xref ref-type="table" rid="T4">4</xref>).</p><p>Further replication will require a dataset at least as large, with appropriate statistical control for differences between individual sample-sets. Underpowered studies are unhelpful, since chance can produce misleading results in such cases. This criticism may apply to a previous study of this interaction that had power of &#x0003c; 2% to detect it. Even the large Rotterdam Study, with 395 cases of AD and 5,111 controls, only had 40% power to detect this interaction. Thus, further replication may require a meta-analysis.</p><sec><title>IL-6 in age-related decline and in AD</title><p>There is much evidence that chronic, low-grade overexpression of IL-6 contributes to age-related decline. Blood levels of IL-6 can rise with age in humans [<xref ref-type="bibr" rid="B22">22</xref>-<xref ref-type="bibr" rid="B24">24</xref>]. Raised levels are associated with various age-related conditions, including risk of cognitive decline in some studies [<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B26">26</xref>], but not in all [<xref ref-type="bibr" rid="B27">27</xref>]. Raised levels have been consistently associated with increased mortality in several large prospective studies [<xref ref-type="bibr" rid="B28">28</xref>-<xref ref-type="bibr" rid="B31">31</xref>]. Raised levels have also been associated with various conditions considered to be risk factors for dementia and/or AD: subclinical and clinical cardiovascular disease and the risk thereof [<xref ref-type="bibr" rid="B32">32</xref>-<xref ref-type="bibr" rid="B34">34</xref>], type 2 diabetes and its risk [<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B36">36</xref>], psychological stress [<xref ref-type="bibr" rid="B37">37</xref>] and the damage following stroke (IL-6 also increased in CSF) [<xref ref-type="bibr" rid="B38">38</xref>,<xref ref-type="bibr" rid="B39">39</xref>].</p><p>Further, raised blood levels of IL-6 have often been associated with AD [<xref ref-type="bibr" rid="B40">40</xref>-<xref ref-type="bibr" rid="B42">42</xref>] and also with the risk of AD [<xref ref-type="bibr" rid="B43">43</xref>], although not in all studies [<xref ref-type="bibr" rid="B44">44</xref>,<xref ref-type="bibr" rid="B45">45</xref>]. Post-mortem studies, although small, have generally reported increased IL-6 levels or changed IL-6 distribution in AD brain [<xref ref-type="bibr" rid="B46">46</xref>-<xref ref-type="bibr" rid="B49">49</xref>], with one exception [<xref ref-type="bibr" rid="B50">50</xref>]. IL-6 was found not only in plaques, but also around the bodies of isocortical neurones, only in AD [<xref ref-type="bibr" rid="B46">46</xref>]. This evidence and that above suggest that dysregulation of IL-6 contributes to the development of AD.</p></sec><sec><title>A potential interaction between <italic>IL6</italic> and <italic>IL10</italic></title><p>Both IL-6 and IL-10 are produced by activated microglia and astrocytes (reviewed in [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]). However, in contrast to IL-6, IL-10 acts to limit inflammation in the brain. IL-10 inhibits the production of IL-6 [<xref ref-type="bibr" rid="B51">51</xref>,<xref ref-type="bibr" rid="B52">52</xref>] and its receptor [<xref ref-type="bibr" rid="B53">53</xref>]. Thus, certain combinations of genetic variants of <italic>IL6 </italic>and <italic>IL10</italic>, i.e. those associated with high production of IL-6 combined with those associated with low production of IL-10, may contribute to the dysregulation of inflammation. High heritability (&#x0003e; 50%) has been reported for <italic>in vitro </italic>stimulated production of both IL-6 and IL-10 [<xref ref-type="bibr" rid="B54">54</xref>]. The functions of two of our studied SNPs, <italic>IL6 </italic>intron 2 A/G and <italic>IL10 </italic>3' C/T have not yet been investigated. Thus we cannot rule out that they might have effects on transcription or post-transcriptional processing. Alternatively, they may be in linkage disequilibrium with other, functional variants. On the other hand, studies of <italic>IL6</italic>-174G/C [<xref ref-type="bibr" rid="B55">55</xref>,<xref ref-type="bibr" rid="B56">56</xref>], of <italic>IL10</italic>-819C/T [<xref ref-type="bibr" rid="B57">57</xref>] and of <italic>IL10</italic>-1082G/A [<xref ref-type="bibr" rid="B58">58</xref>-<xref ref-type="bibr" rid="B60">60</xref>] have reported that these SNPs affect transcription or are in linkage disequilibrium with those that do. However, it may be premature to designate any particular alleles as high or low producers, since there have been contrasting results for the effects of <italic>IL6</italic>-174G/C and <italic>IL10</italic>-1082G/A on transcription, on <italic>in vitro </italic>stimulated production and on blood levels of the respective proteins. But most studies have associated the <italic>IL10</italic>-1082GG genotype at least with higher <italic>in vitro </italic>stimulated production of IL-10 [<xref ref-type="bibr" rid="B61">61</xref>-<xref ref-type="bibr" rid="B64">64</xref>], although not all, [<xref ref-type="bibr" rid="B65">65</xref>,<xref ref-type="bibr" rid="B66">66</xref>] and results have varied with experimental conditions [<xref ref-type="bibr" rid="B64">64</xref>,<xref ref-type="bibr" rid="B66">66</xref>]. It appears that several SNPs in the regulatory regions of each gene affect transcription in an interactive and tissue-specific manner [<xref ref-type="bibr" rid="B56">56</xref>]. Indeed, we note that in our dataset the 2-SNP combination of <italic>IL10 -1082G+/-819CC</italic> has a slightly stronger interaction with <italic>IL6 </italic>than that of either SNP alone (data not shown).</p></sec></sec><sec><title>Conclusion</title><p>We conclude that an interaction between IL-6 and IL-10 is plausible; that dysregulation of the two genes contributes to chronic low-grade inflammation in some elderly people and thus to the risk of AD; and that certain combinations of genetic variants in the regulatory regions of the two genes are conducive to this dysregulation. But in view of the linkage disequilibrium in the region of each gene (Table <xref ref-type="table" rid="T2">2</xref>), we cannot conclude that we have yet found the true risk polymorphisms. However, we suggest that our results are consistent with the contribution of inflammation to the onset of AD.</p></sec><sec><title>Abbreviations</title><p>AD: Alzheimer's disease; <italic>APOE</italic>&#x003b5;4: apolipoprotein E &#x003b5;4; CERAD: Consortium to Establish a Registry for Alzheimer's Disease; CSF: cerebrospinal fluid; IL-6: interleukin-6; <italic>IL6</italic>: the gene for interleukin-6; IL-10: interleukin-10; <italic>IL10</italic>: the gene for interleukin-10; NINCDS-ADRDA: National Institute of Neurological, Communicative Diseases and Stroke-Alzheimer's Disease and Related Diseases Association; OPTIMA: the Oxford Project to Investigate Memory and Ageing; <italic>SF</italic>: synergy factor; SNP: single nucleotide polymorphism.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>All authors contributed to the design of the study. In addition, ADS and DJL set up the Epistasis Project, with the help of the other authors. ADS and DJL decided on the strategy of the Epistasis Project, with the help of CMvD, OC, KM, PK, R Heun, MC-B, DRW and EC. ADS, DJL, CMvD, OC, KM, PK, R Heun, MC-B, DRW and EC chose the genetic interactions to study. OC produced the hypothesis for this study. KM and OB gave extensive advice on the choice of SNPs to study. DJL made the final selection of polymorphisms. HK, R Harrison, KM, DRW, EC and IM provided DNA for genotyping. CMvD, YSA, AA-V and MS provided the data for the preliminary study. DRW gave technical advice throughout. RG and NH were responsible for the genotyping of 6 sample-sets. AA-V was responsible for the Rotterdam genotyping. MC-B and DJL decided on the analytical approach. MC-B and YSA advised on statistics throughout. DJL and MGL performed the analysis. DJL drafted the manuscript. OC submitted the manuscript and is responsible for correspondence. All authors read the manuscript, studied it critically for its intellectual content and approved the final draft.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>The seven centres of the Epistasis Project</bold>.</p></caption><media xlink:href="1742-2094-6-22-S1.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>We are most grateful to the Moulton Charitable Foundation for a grant to fund the Epistasis Project and to all those who have provided support for the individual clinical studies. GW was partly supported by the NIHR Biomedical Research Centre, Oxford. UCL Institute of Child Health receives funding from the Department of Health's NIHR Biomedical Research Centres funding scheme. The Centre for Paediatric Epidemiology and Biostatistics also benefits from funding support from the Medical Research Council in its capacity as the MRC Centre of Epidemiology for Child Health (G0400546).</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akiyama</surname><given-names>H</given-names></name><name><surname>Barger</surname><given-names>S</given-names></name><name><surname>Barnum</surname><given-names>S</given-names></name><name><surname>Bradt</surname><given-names>B</given-names></name><name><surname>Bauer</surname><given-names>J</given-names></name><name><surname>Cole</surname><given-names>GM</given-names></name><name><surname>Cooper</surname><given-names>NR</given-names></name><name><surname>Eikelenboom</surname><given-names>P</given-names></name><name><surname>Emmerling</surname><given-names>M</given-names></name><name><surname>Fiebich</surname><given-names>BL</given-names></name><etal></etal></person-group><article-title>Inflammation and Alzheimer's disease</article-title><source>Neurobiol Aging</source><year>2000</year><volume>21</volume><fpage>383</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">10858586</pub-id><pub-id pub-id-type="doi">10.1016/S0197-4580(00)00124-X</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>J</given-names></name><name><surname>Webster</surname><given-names>S</given-names></name><name><surname>Lue</surname><given-names>L-F</given-names></name><name><surname>Brachova</surname><given-names>L</given-names></name><name><surname>Civin</surname><given-names>WH</given-names></name><name><surname>Emmerling</surname><given-names>M</given-names></name><name><surname>Shivers</surname><given-names>B</given-names></name><name><surname>Walker</surname><given-names>D</given-names></name><name><surname>McGeer</surname><given-names>P</given-names></name></person-group><article-title>Inflammation and Alzheimer's disease pathogenesis</article-title><source>Neurobiol Aging</source><year>1996</year><volume>17</volume><fpage>681</fpage><lpage>686</lpage><pub-id pub-id-type="pmid">8892340</pub-id><pub-id pub-id-type="doi">10.1016/0197-4580(96)00115-7</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gruol</surname><given-names>DL</given-names></name><name><surname>Nelson</surname><given-names>TE</given-names></name></person-group><article-title>Physiological and pathological roles of interleukin-6 in the central nervous system</article-title><source>Mol Neurobiol</source><year>1997</year><volume>15</volume><fpage>307</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">9457704</pub-id><pub-id pub-id-type="doi">10.1007/BF02740665</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strle</surname><given-names>K</given-names></name><name><surname>Zhou</surname><given-names>JH</given-names></name><name><surname>Shen</surname><given-names>W-H</given-names></name><name><surname>Broussard</surname><given-names>SR</given-names></name><name><surname>Johnson</surname><given-names>RW</given-names></name><name><surname>Freund</surname><given-names>GG</given-names></name><name><surname>Dantzer</surname><given-names>R</given-names></name><name><surname>Kelley</surname><given-names>KW</given-names></name></person-group><article-title>Interleukin-10 in the brain</article-title><source>Crit Rev Immunol</source><year>2001</year><volume>21</volume><fpage>427</fpage><lpage>449</lpage><pub-id pub-id-type="pmid">11942558</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bertram</surname><given-names>L</given-names></name><name><surname>McQueen</surname><given-names>MB</given-names></name><name><surname>Mullin</surname><given-names>K</given-names></name><name><surname>Blacker</surname><given-names>D</given-names></name><name><surname>Tanzi</surname><given-names>RE</given-names></name></person-group><article-title>Systematic meta-analyses of Alzheimer disease genetic association studies: the Alzgene database</article-title><source>Nature Genetics</source><year>2007</year><volume>39</volume><fpage>17</fpage><lpage>23</lpage><comment>Accessed on 14 July, 2009.</comment><pub-id pub-id-type="pmid">17192785</pub-id><pub-id pub-id-type="doi">10.1038/ng1934</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>JH</given-names></name><name><surname>Williams</surname><given-names>SM</given-names></name></person-group><article-title>Traversing the conceptual divide between biological and statistical epistasis: systems biology and a more modern synthesis</article-title><source>BioEssays</source><year>2005</year><volume>27</volume><fpage>637</fpage><lpage>646</lpage><pub-id pub-id-type="pmid">15892116</pub-id><pub-id pub-id-type="doi">10.1002/bies.20236</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wade</surname><given-names>MJ</given-names></name></person-group><article-title>Epistasis, complex traits, and mapping genes</article-title><source>Genetica</source><year>2001</year><volume>112&#x02013;113</volume><fpage>59</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">11838787</pub-id><pub-id pub-id-type="doi">10.1023/A:1013316611768</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Infante</surname><given-names>J</given-names></name><name><surname>Sanz</surname><given-names>C</given-names></name><name><surname>Fern&#x000e1;ndez-Luna</surname><given-names>JL</given-names></name><name><surname>Llorca</surname><given-names>J</given-names></name><name><surname>Berciano</surname><given-names>J</given-names></name><name><surname>Combarros</surname><given-names>O</given-names></name></person-group><article-title>Gene-gene interaction between interleukin-6 and interleukin-10 reduces AD risk</article-title><source>Neurology</source><year>2004</year><volume>63</volume><fpage>1135</fpage><lpage>1136</lpage><pub-id pub-id-type="pmid">15452323</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bergem</surname><given-names>ALM</given-names></name><name><surname>Engedal</surname><given-names>K</given-names></name><name><surname>Kringlen</surname><given-names>E</given-names></name></person-group><article-title>The role of heredity in late-onset Alzheimer disease and vascular dementia &#x02013; a twin study</article-title><source>Arch Gen Psychiatry</source><year>1997</year><volume>54</volume><fpage>264</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">9075467</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cortina-Borja</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>AD</given-names></name><name><surname>Combarros</surname><given-names>O</given-names></name><name><surname>Lehmann</surname><given-names>DJ</given-names></name></person-group><article-title>The synergy factor: a statistic to measure interactions in complex diseases</article-title><source>BMC Res Notes</source><year>2009</year><volume>2</volume><fpage>105</fpage><pub-id pub-id-type="pmid">19527493</pub-id><pub-id pub-id-type="doi">10.1186/1756-0500-2-105</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mirra</surname><given-names>SS</given-names></name><name><surname>Heyman</surname><given-names>A</given-names></name><name><surname>McKeel</surname><given-names>D</given-names></name><name><surname>Sumi</surname><given-names>SM</given-names></name><name><surname>Crain</surname><given-names>BJ</given-names></name><name><surname>Brownlee</surname><given-names>LM</given-names></name><name><surname>Vogel</surname><given-names>FS</given-names></name><name><surname>Hughes</surname><given-names>JP</given-names></name><name><surname>van Belle</surname><given-names>G</given-names></name><name><surname>Berg</surname><given-names>L</given-names></name></person-group><article-title>The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease</article-title><source>Neurology</source><year>1991</year><volume>41</volume><fpage>479</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">2011243</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McKhann</surname><given-names>G</given-names></name><name><surname>Drachman</surname><given-names>D</given-names></name><name><surname>Folstein</surname><given-names>M</given-names></name><name><surname>Katzman</surname><given-names>R</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Stadlan</surname><given-names>EM</given-names></name></person-group><article-title>Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease</article-title><source>Neurology</source><year>1984</year><volume>34</volume><fpage>939</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">6610841</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Combarros</surname><given-names>O</given-names></name><name><surname>Cortina-Borja</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>AD</given-names></name><name><surname>Lehmann</surname><given-names>DJ</given-names></name></person-group><article-title>Epistasis in sporadic Alzheimer's disease</article-title><source>Neurobiol Aging</source><year>2009</year><volume>30</volume><fpage>1333</fpage><lpage>1349</lpage><pub-id pub-id-type="pmid">18206267</pub-id><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2007.11.027</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>CJ</given-names></name></person-group><article-title>Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis</article-title><source>Neurochem Int</source><year>2007</year><volume>50</volume><fpage>12</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">16973241</pub-id><pub-id pub-id-type="doi">10.1016/j.neuint.2006.07.007</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><article-title>The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics</article-title><source>Science</source><year>2002</year><volume>297</volume><fpage>353</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">12130773</pub-id><pub-id pub-id-type="doi">10.1126/science.1072994</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>G</given-names></name><name><surname>Nunomura</surname><given-names>A</given-names></name><name><surname>Hirai</surname><given-names>K</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>P&#x000e9;rez</surname><given-names>M</given-names></name><name><surname>Avila</surname><given-names>J</given-names></name><name><surname>Castellani</surname><given-names>RJ</given-names></name><name><surname>Atwood</surname><given-names>CS</given-names></name><name><surname>Aliev</surname><given-names>G</given-names></name><name><surname>Sayre</surname><given-names>LM</given-names></name><etal></etal></person-group><article-title>Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases?</article-title><source>Free Rad Biol Med</source><year>2002</year><volume>33</volume><fpage>1475</fpage><lpage>1479</lpage><pub-id pub-id-type="pmid">12446204</pub-id><pub-id pub-id-type="doi">10.1016/S0891-5849(02)01113-9</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Craft</surname><given-names>S</given-names></name></person-group><article-title>The role of metabolic disorders in Alzheimer disease and vascular dementia</article-title><source>Arch Neurol</source><year>2009</year><volume>66</volume><fpage>300</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">19273747</pub-id><pub-id pub-id-type="doi">10.1001/archneurol.2009.27</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>AD</given-names></name></person-group><article-title>The worldwide challenge of the dementias: a role for B vitamins and homocysteine?</article-title><source>Food Nutr Bull</source><year>2008</year><volume>29</volume><fpage>S143</fpage><lpage>S172</lpage><pub-id pub-id-type="pmid">18709889</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ikram</surname><given-names>MA</given-names></name><name><surname>Seshadri</surname><given-names>S</given-names></name><name><surname>Bis</surname><given-names>JC</given-names></name><name><surname>Fornage</surname><given-names>M</given-names></name><name><surname>DeStefano</surname><given-names>AL</given-names></name><name><surname>Aulchenko</surname><given-names>YS</given-names></name><name><surname>Debette</surname><given-names>S</given-names></name><name><surname>Lumley</surname><given-names>T</given-names></name><name><surname>Folsom</surname><given-names>AR</given-names></name><name><surname>van den Herik</surname><given-names>EG</given-names></name><etal></etal></person-group><article-title>Genomewide association studies of stroke</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><fpage>1718</fpage><lpage>1728</lpage><pub-id pub-id-type="pmid">19369658</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa0900094</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DerSimonian</surname><given-names>R</given-names></name><name><surname>Laird</surname><given-names>N</given-names></name></person-group><article-title>Meta-analysis in clinical trials</article-title><source>Control Clin Trials</source><year>1986</year><volume>7</volume><fpage>177</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">3802833</pub-id><pub-id pub-id-type="doi">10.1016/0197-2456(86)90046-2</pub-id></citation></ref><ref id="B21"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Armitage</surname><given-names>P</given-names></name></person-group><source>Statistical Methods in Medical Research</source><year>1983</year><publisher-name>Oxford: Blackwell Scientific Publications</publisher-name></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ershler</surname><given-names>WB</given-names></name></person-group><article-title>Interleukin-6: a cytokine for gerontologists</article-title><source>J Am Geriatr Soc</source><year>1993</year><volume>41</volume><fpage>176</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">8426042</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hager</surname><given-names>K</given-names></name><name><surname>Machein</surname><given-names>U</given-names></name><name><surname>Krieger</surname><given-names>S</given-names></name><name><surname>Platt</surname><given-names>D</given-names></name><name><surname>Seefried</surname><given-names>G</given-names></name><name><surname>Bauer</surname><given-names>J</given-names></name></person-group><article-title>Interleukin-6 and selected plasma proteins in healthy persons of different ages</article-title><source>Neurobiol Aging</source><year>1994</year><volume>15</volume><fpage>771</fpage><lpage>772</lpage><pub-id pub-id-type="pmid">7534383</pub-id><pub-id pub-id-type="doi">10.1016/0197-4580(94)90066-3</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>DG</given-names></name><name><surname>Skibinski</surname><given-names>G</given-names></name><name><surname>Mason</surname><given-names>JI</given-names></name><name><surname>James</surname><given-names>K</given-names></name></person-group><article-title>The influence of age and gender on serum dehydroepiandrosterone sulphate (DHEA-S), IL-6, IL-6 soluble receptor (IL-6 sR) and transforming growth factor &#x003b2;1 (TGF-&#x003b2;1) levels in normal healthy blood donors</article-title><source>Clin Exp Immunol</source><year>1999</year><volume>117</volume><fpage>476</fpage><lpage>481</lpage><pub-id pub-id-type="pmid">10469050</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2249.1999.01003.x</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weaver</surname><given-names>JD</given-names></name><name><surname>Huang</surname><given-names>M-H</given-names></name><name><surname>Albert</surname><given-names>M</given-names></name><name><surname>Harris</surname><given-names>T</given-names></name><name><surname>Rowe</surname><given-names>JW</given-names></name><name><surname>Seeman</surname><given-names>TE</given-names></name></person-group><article-title>Interleukin-6 and risk of cognitive decline</article-title><source>Neurology</source><year>2002</year><volume>59</volume><fpage>371</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">12177370</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yaffe</surname><given-names>K</given-names></name><name><surname>Lindquist</surname><given-names>K</given-names></name><name><surname>Penninx</surname><given-names>BW</given-names></name><name><surname>Simonsick</surname><given-names>EM</given-names></name><name><surname>Pahor</surname><given-names>M</given-names></name><name><surname>Kritchevsky</surname><given-names>S</given-names></name><name><surname>Launer</surname><given-names>L</given-names></name><name><surname>Kuller</surname><given-names>L</given-names></name><name><surname>Rubin</surname><given-names>S</given-names></name><name><surname>Harris</surname><given-names>T</given-names></name></person-group><article-title>Inflammatory markers and cognition in well-functioning African-American and white elders</article-title><source>Neurology</source><year>2003</year><volume>61</volume><fpage>76</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">12847160</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dik</surname><given-names>MG</given-names></name><name><surname>Jonker</surname><given-names>C</given-names></name><name><surname>Hack</surname><given-names>CE</given-names></name><name><surname>Smit</surname><given-names>JH</given-names></name><name><surname>Comijs</surname><given-names>HC</given-names></name><name><surname>Eikelenboom</surname><given-names>P</given-names></name></person-group><article-title>Serum inflammatory proteins and cognitive decline in older persons</article-title><source>Neurology</source><year>2005</year><volume>64</volume><fpage>1371</fpage><lpage>1377</lpage><pub-id pub-id-type="pmid">15851726</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>HJ</given-names></name><name><surname>Harris</surname><given-names>T</given-names></name><name><surname>Peiper</surname><given-names>CF</given-names></name></person-group><article-title>Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly</article-title><source>Am J Med</source><year>2003</year><volume>114</volume><fpage>180</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">12637131</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9343(02)01484-5</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>TB</given-names></name><name><surname>Ferrucci</surname><given-names>L</given-names></name><name><surname>Tracy</surname><given-names>RP</given-names></name><name><surname>Corti</surname><given-names>M-C</given-names></name><name><surname>Wacholder</surname><given-names>S</given-names></name><name><surname>Ettinger</surname><given-names>WHJ</given-names></name><name><surname>Heimovitz</surname><given-names>H</given-names></name><name><surname>Cohen</surname><given-names>HJ</given-names></name><name><surname>Wallace</surname><given-names>R</given-names></name></person-group><article-title>Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly</article-title><source>Am J Med</source><year>1999</year><volume>106</volume><fpage>506</fpage><lpage>512</lpage><pub-id pub-id-type="pmid">10335721</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9343(99)00066-2</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reuben</surname><given-names>DB</given-names></name><name><surname>Cheh</surname><given-names>AI</given-names></name><name><surname>Harris</surname><given-names>TB</given-names></name><name><surname>Ferrucci</surname><given-names>L</given-names></name><name><surname>Rowe</surname><given-names>JW</given-names></name><name><surname>Tracy</surname><given-names>RP</given-names></name><name><surname>Seeman</surname><given-names>TE</given-names></name></person-group><article-title>Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons</article-title><source>J Am Geriatr Soc</source><year>2002</year><volume>50</volume><fpage>638</fpage><lpage>644</lpage><pub-id pub-id-type="pmid">11982663</pub-id><pub-id pub-id-type="doi">10.1046/j.1532-5415.2002.50157.x</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Volpato</surname><given-names>S</given-names></name><name><surname>Guralnik</surname><given-names>JM</given-names></name><name><surname>Ferrucci</surname><given-names>L</given-names></name><name><surname>Balfour</surname><given-names>J</given-names></name><name><surname>Chaves</surname><given-names>P</given-names></name><name><surname>Fried</surname><given-names>LP</given-names></name><name><surname>Harris</surname><given-names>TB</given-names></name></person-group><article-title>Cardiovascular disease, interleukin-6, and risk of mortality in older women: the Women's Health and Aging Study</article-title><source>Circulation</source><year>2001</year><volume>103</volume><fpage>947</fpage><lpage>953</lpage><pub-id pub-id-type="pmid">11181468</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cesari</surname><given-names>M</given-names></name><name><surname>Penninx</surname><given-names>BW</given-names></name><name><surname>Newman</surname><given-names>AB</given-names></name><name><surname>Kritchevsky</surname><given-names>SB</given-names></name><name><surname>Nicklas</surname><given-names>BJ</given-names></name><name><surname>Sutton-Tyrrell</surname><given-names>K</given-names></name><name><surname>Rubin</surname><given-names>SM</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Simonsick</surname><given-names>EM</given-names></name><name><surname>Harris</surname><given-names>TB</given-names></name><etal></etal></person-group><article-title>Inflammatory markers and onset of cardiovascular events: results from the Health ABC study</article-title><source>Circulation</source><year>2003</year><volume>108</volume><fpage>2317</fpage><lpage>2322</lpage><pub-id pub-id-type="pmid">14568895</pub-id><pub-id pub-id-type="doi">10.1161/01.CIR.0000097109.90783.FC</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cesari</surname><given-names>M</given-names></name><name><surname>Penninx</surname><given-names>BW</given-names></name><name><surname>Newman</surname><given-names>AB</given-names></name><name><surname>Kritchevsky</surname><given-names>SB</given-names></name><name><surname>Nicklas</surname><given-names>BJ</given-names></name><name><surname>Sutton-Tyrrell</surname><given-names>K</given-names></name><name><surname>Tracy</surname><given-names>RP</given-names></name><name><surname>Rubin</surname><given-names>SM</given-names></name><name><surname>Harris</surname><given-names>TB</given-names></name><name><surname>Pahor</surname><given-names>M</given-names></name></person-group><article-title>Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] study)</article-title><source>Am J Cardiol</source><year>2003</year><volume>92</volume><fpage>522</fpage><lpage>528</lpage><pub-id pub-id-type="pmid">12943870</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9149(03)00718-5</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Hennekens</surname><given-names>CH</given-names></name></person-group><article-title>Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men</article-title><source>Circulation</source><year>2000</year><volume>101</volume><fpage>1767</fpage><lpage>1772</lpage><pub-id pub-id-type="pmid">10769275</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pradhan</surname><given-names>AD</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name><name><surname>Buring</surname><given-names>JE</given-names></name><name><surname>Ridker</surname><given-names>PM</given-names></name></person-group><article-title>C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus</article-title><source>JAMA</source><year>2001</year><volume>286</volume><fpage>327</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">11466099</pub-id><pub-id pub-id-type="doi">10.1001/jama.286.3.327</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Testa</surname><given-names>R</given-names></name><name><surname>Olivieri</surname><given-names>F</given-names></name><name><surname>Bonfigli</surname><given-names>AR</given-names></name><name><surname>Sirolla</surname><given-names>C</given-names></name><name><surname>Boemi</surname><given-names>M</given-names></name><name><surname>Marchegiani</surname><given-names>F</given-names></name><name><surname>Marra</surname><given-names>M</given-names></name><name><surname>Cenerelli</surname><given-names>S</given-names></name><name><surname>Antonicelli</surname><given-names>R</given-names></name><name><surname>Dolci</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Interleukin-6-174G&#x0003e;C polymorphism affects the association between IL-6 plasma levels and insulin resistance in type 2 diabetic patients</article-title><source>Diabetes Res Clin Pract</source><year>2006</year><volume>71</volume><fpage>299</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">16140413</pub-id><pub-id pub-id-type="doi">10.1016/j.diabres.2005.07.007</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kiecolt-Glaser</surname><given-names>JK</given-names></name><name><surname>Preacher</surname><given-names>KJ</given-names></name><name><surname>MacCullum</surname><given-names>RC</given-names></name><name><surname>Atkinson</surname><given-names>C</given-names></name><name><surname>Malarkey</surname><given-names>WB</given-names></name><name><surname>Glaser</surname><given-names>R</given-names></name></person-group><article-title>Chronic stress and age-related increases in the proinflammatory cytokine IL-6</article-title><source>Proc Natl Acad Sci USA</source><year>2003</year><volume>100</volume><fpage>9090</fpage><lpage>9095</lpage><pub-id pub-id-type="pmid">12840146</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1531903100</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Castellanos</surname><given-names>M</given-names></name><name><surname>Castillo</surname><given-names>J</given-names></name><name><surname>Garc&#x000ed;a</surname><given-names>MM</given-names></name><name><surname>Leira</surname><given-names>R</given-names></name><name><surname>Serena</surname><given-names>J</given-names></name><name><surname>Chamorro</surname><given-names>A</given-names></name><name><surname>D&#x000e1;valos</surname><given-names>A</given-names></name></person-group><article-title>Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target</article-title><source>Stroke</source><year>2002</year><volume>33</volume><fpage>982</fpage><lpage>987</lpage><pub-id pub-id-type="pmid">11935048</pub-id><pub-id pub-id-type="doi">10.1161/hs0402.105339</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tarkowski</surname><given-names>E</given-names></name><name><surname>Rosengren</surname><given-names>L</given-names></name><name><surname>Blomstrand</surname><given-names>C</given-names></name><name><surname>Wikkels&#x000f6;</surname><given-names>C</given-names></name><name><surname>Jensen</surname><given-names>C</given-names></name><name><surname>Ekholm</surname><given-names>S</given-names></name><name><surname>Tarkowski</surname><given-names>A</given-names></name></person-group><article-title>Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke</article-title><source>Stroke</source><year>1995</year><volume>26</volume><fpage>1393</fpage><lpage>1398</lpage><pub-id pub-id-type="pmid">7631343</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baranowska-Bik</surname><given-names>A</given-names></name><name><surname>Bik</surname><given-names>W</given-names></name><name><surname>Wolinska-Witort</surname><given-names>E</given-names></name><name><surname>Martynska</surname><given-names>L</given-names></name><name><surname>Chmielowska</surname><given-names>M</given-names></name><name><surname>Barcikowska</surname><given-names>M</given-names></name><name><surname>Baranowska</surname><given-names>B</given-names></name></person-group><article-title>Plasma &#x003b2; amyloid and cytokine profile in women with Alzheimer's disease</article-title><source>Neuro Endocrinol Lett</source><year>2008</year><volume>29</volume><fpage>75</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">18283248</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bermejo</surname><given-names>P</given-names></name><name><surname>Mart&#x000ed;n-Arag&#x000f3;n</surname><given-names>S</given-names></name><name><surname>Bened&#x000ed;</surname><given-names>J</given-names></name><name><surname>Sus&#x000ed;n</surname><given-names>C</given-names></name><name><surname>Felici</surname><given-names>E</given-names></name><name><surname>Gil</surname><given-names>P</given-names></name><name><surname>Ribera</surname><given-names>JM</given-names></name><name><surname>Villar</surname><given-names>&#x000c1;M</given-names></name></person-group><article-title>Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease</article-title><source>Immunol Lett</source><year>2008</year><volume>117</volume><fpage>198</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">18367253</pub-id><pub-id pub-id-type="doi">10.1016/j.imlet.2008.02.002</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Licastro</surname><given-names>F</given-names></name><name><surname>Pedrini</surname><given-names>S</given-names></name><name><surname>Caputo</surname><given-names>L</given-names></name><name><surname>Annoni</surname><given-names>G</given-names></name><name><surname>Davis</surname><given-names>LJ</given-names></name><name><surname>Ferri</surname><given-names>C</given-names></name><name><surname>Casadei</surname><given-names>V</given-names></name><name><surname>Grimaldi</surname><given-names>LME</given-names></name></person-group><article-title>Increased plasma levels of interleukin-1, interleukin-6 and &#x003b1;-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?</article-title><source>J Neuroimmunol</source><year>2000</year><volume>103</volume><fpage>97</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">10674995</pub-id><pub-id pub-id-type="doi">10.1016/S0165-5728(99)00226-X</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Engelhart</surname><given-names>MJ</given-names></name><name><surname>Geerlings</surname><given-names>MI</given-names></name><name><surname>Meijer</surname><given-names>J</given-names></name><name><surname>Kiliaan</surname><given-names>A</given-names></name><name><surname>Ruitenberg</surname><given-names>A</given-names></name><name><surname>van Swieten</surname><given-names>JC</given-names></name><name><surname>Stijnen</surname><given-names>T</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Witteman</surname><given-names>JC</given-names></name><name><surname>Breteler</surname><given-names>MM</given-names></name></person-group><article-title>Inflammatory proteins in plasma and the risk of dementia: the Rotterdam Study</article-title><source>Arch Neurol</source><year>2004</year><volume>61</volume><fpage>668</fpage><lpage>672</lpage><pub-id pub-id-type="pmid">15148142</pub-id><pub-id pub-id-type="doi">10.1001/archneur.61.5.668</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ravaglia</surname><given-names>G</given-names></name><name><surname>Forti</surname><given-names>P</given-names></name><name><surname>Maioli</surname><given-names>F</given-names></name><name><surname>Chiappelli</surname><given-names>M</given-names></name><name><surname>Montesi</surname><given-names>F</given-names></name><name><surname>Tumini</surname><given-names>E</given-names></name><name><surname>Mariani</surname><given-names>E</given-names></name><name><surname>Licastro</surname><given-names>F</given-names></name><name><surname>Patterson</surname><given-names>C</given-names></name></person-group><article-title>Blood inflammatory markers and risk of dementia: the Conselice Study of Brain Aging</article-title><source>Neurobiol Aging</source><year>2007</year><volume>28</volume><fpage>1810</fpage><lpage>1820</lpage><pub-id pub-id-type="pmid">17011077</pub-id><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2006.08.012</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Nagelkerken</surname><given-names>L</given-names></name></person-group><article-title>Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease</article-title><source>Neurosci Lett</source><year>1990</year><volume>108</volume><fpage>350</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">2304653</pub-id><pub-id pub-id-type="doi">10.1016/0304-3940(90)90666-W</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>J</given-names></name><name><surname>Strauss</surname><given-names>S</given-names></name><name><surname>Schreiter-Gasser</surname><given-names>U</given-names></name><name><surname>Ganter</surname><given-names>U</given-names></name><name><surname>Schlegel</surname><given-names>P</given-names></name><name><surname>Witt</surname><given-names>I</given-names></name><name><surname>Yolk</surname><given-names>B</given-names></name><name><surname>Berger</surname><given-names>M</given-names></name></person-group><article-title>Interleukin-6 and &#x003b1;-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices</article-title><source>FEBS Lett</source><year>1991</year><volume>285</volume><fpage>111</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">1712317</pub-id><pub-id pub-id-type="doi">10.1016/0014-5793(91)80737-N</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Haslinger</surname><given-names>A</given-names></name><name><surname>Scheloske</surname><given-names>M</given-names></name><name><surname>Padberg</surname><given-names>F</given-names></name><name><surname>Fischer</surname><given-names>P</given-names></name><name><surname>Unger</surname><given-names>J</given-names></name><name><surname>Teipel</surname><given-names>SJ</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Rosenberg</surname><given-names>C</given-names></name><name><surname>Oshida</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain</article-title><source>Eur Arch Psychiatry Clin Neurosci</source><year>2005</year><volume>255</volume><fpage>269</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">15565298</pub-id><pub-id pub-id-type="doi">10.1007/s00406-004-0558-2</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luterman</surname><given-names>JD</given-names></name><name><surname>Haroutunian</surname><given-names>V</given-names></name><name><surname>Yemul</surname><given-names>S</given-names></name><name><surname>Ho</surname><given-names>L</given-names></name><name><surname>Purohit</surname><given-names>D</given-names></name><name><surname>Aisen</surname><given-names>PS</given-names></name><name><surname>Mohs</surname><given-names>R</given-names></name><name><surname>Pasinetti</surname><given-names>GM</given-names></name></person-group><article-title>Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia</article-title><source>Arch Neurol</source><year>2000</year><volume>57</volume><fpage>1153</fpage><lpage>1160</lpage><pub-id pub-id-type="pmid">10927795</pub-id><pub-id pub-id-type="doi">10.1001/archneur.57.8.1153</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>JA</given-names></name><name><surname>Wood</surname><given-names>PL</given-names></name><name><surname>Ryan</surname><given-names>R</given-names></name><name><surname>Graff-Radford</surname><given-names>NR</given-names></name><name><surname>Pilapil</surname><given-names>C</given-names></name><name><surname>Robitaille</surname><given-names>Y</given-names></name><name><surname>Quirion</surname><given-names>R</given-names></name></person-group><article-title>Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1&#x003b2; or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein</article-title><source>Brain Res</source><year>1993</year><volume>629</volume><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">7509248</pub-id><pub-id pub-id-type="doi">10.1016/0006-8993(93)91327-O</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lanzrein</surname><given-names>AS</given-names></name><name><surname>Johnston</surname><given-names>CM</given-names></name><name><surname>Perry</surname><given-names>VH</given-names></name><name><surname>Jobst</surname><given-names>KA</given-names></name><name><surname>King</surname><given-names>EM</given-names></name><name><surname>Smith</surname><given-names>AD</given-names></name></person-group><article-title>Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin</article-title><source>Alzheimer Dis Assoc Disord</source><year>1998</year><volume>12</volume><fpage>215</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">9772027</pub-id><pub-id pub-id-type="doi">10.1097/00002093-199809000-00016</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heyen</surname><given-names>JR</given-names></name><name><surname>Ye</surname><given-names>S</given-names></name><name><surname>Finck</surname><given-names>BN</given-names></name><name><surname>Johnson</surname><given-names>RW</given-names></name></person-group><article-title>Interleukin (IL)-10 inhibits IL-6 production in microglia by preventing activation of NF&#x003ba; B</article-title><source>Brain Res Mol Brain Res</source><year>2000</year><volume>77</volume><fpage>138</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">10814840</pub-id><pub-id pub-id-type="doi">10.1016/S0169-328X(00)00042-5</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Szczepanik</surname><given-names>AM</given-names></name><name><surname>Funes</surname><given-names>S</given-names></name><name><surname>Petko</surname><given-names>W</given-names></name><name><surname>Ringheim</surname><given-names>GE</given-names></name></person-group><article-title>IL-4, IL-10 and IL-13 modulate A&#x003b2; (1&#x02013;42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line</article-title><source>J Neuroimmunol</source><year>2001</year><volume>113</volume><fpage>49</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">11137576</pub-id><pub-id pub-id-type="doi">10.1016/S0165-5728(00)00404-5</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sawada</surname><given-names>M</given-names></name><name><surname>Suzumura</surname><given-names>A</given-names></name><name><surname>Hosoya</surname><given-names>H</given-names></name><name><surname>Marunouchi</surname><given-names>T</given-names></name><name><surname>Nagatsu</surname><given-names>T</given-names></name></person-group><article-title>Interleukin-10 inhibits both production of cytokines and expression of cytokine receptors in microglia</article-title><source>J Neurochem</source><year>1999</year><volume>72</volume><fpage>1466</fpage><lpage>1471</lpage><pub-id pub-id-type="pmid">10098850</pub-id><pub-id pub-id-type="doi">10.1046/j.1471-4159.1999.721466.x</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Posthuma</surname><given-names>D</given-names></name><name><surname>Meulenbelt</surname><given-names>I</given-names></name><name><surname>de Craen</surname><given-names>AJM</given-names></name><name><surname>de Geus</surname><given-names>EJC</given-names></name><name><surname>Slagboom</surname><given-names>PE</given-names></name><name><surname>Boomsma</surname><given-names>DI</given-names></name><name><surname>Westendorp</surname><given-names>RGJ</given-names></name></person-group><article-title>Human cytokine response to <italic>ex vivo </italic>amyloid-&#x003b2; stimulation is mediated by genetic factors</article-title><source>Twin Res Hum Genet</source><year>2005</year><volume>8</volume><fpage>132</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">15901476</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fishman</surname><given-names>D</given-names></name><name><surname>Faulds</surname><given-names>G</given-names></name><name><surname>Jeffery</surname><given-names>R</given-names></name><name><surname>Mohamed-Ali</surname><given-names>V</given-names></name><name><surname>Yudkin</surname><given-names>JS</given-names></name><name><surname>Humphries</surname><given-names>S</given-names></name><name><surname>Woo</surname><given-names>P</given-names></name></person-group><article-title>The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis</article-title><source>J Clin Invest</source><year>1998</year><volume>102</volume><fpage>1369</fpage><lpage>1376</lpage><pub-id pub-id-type="pmid">9769329</pub-id><pub-id pub-id-type="doi">10.1172/JCI2629</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Terry</surname><given-names>CF</given-names></name><name><surname>Loukaci</surname><given-names>V</given-names></name><name><surname>Green</surname><given-names>FR</given-names></name></person-group><article-title>Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>18138</fpage><lpage>18144</lpage><pub-id pub-id-type="pmid">10747905</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M000379200</pub-id></citation></ref><ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rad</surname><given-names>R</given-names></name><name><surname>Dossumbekova</surname><given-names>A</given-names></name><name><surname>Neu</surname><given-names>B</given-names></name><name><surname>Lang</surname><given-names>R</given-names></name><name><surname>Bauer</surname><given-names>S</given-names></name><name><surname>Saur</surname><given-names>D</given-names></name><name><surname>Gerhard</surname><given-names>M</given-names></name><name><surname>Prinz</surname><given-names>C</given-names></name></person-group><article-title>Cytokine gene polymorphisms influence mucosal cytokine expression, gastric inflammation, and host specific colonisation during <italic>Helicobacter pylori </italic>infection</article-title><source>Gut</source><year>2004</year><volume>53</volume><fpage>1082</fpage><lpage>1089</lpage><pub-id pub-id-type="pmid">15247172</pub-id><pub-id pub-id-type="doi">10.1136/gut.2003.029736</pub-id></citation></ref><ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crawley</surname><given-names>E</given-names></name><name><surname>Kay</surname><given-names>R</given-names></name><name><surname>Sillibourne</surname><given-names>J</given-names></name><name><surname>Patel</surname><given-names>P</given-names></name><name><surname>Hutchinson</surname><given-names>I</given-names></name><name><surname>Woo</surname><given-names>P</given-names></name></person-group><article-title>Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis</article-title><source>Arthritis Rheum</source><year>1999</year><volume>42</volume><fpage>1101</fpage><lpage>1108</lpage><pub-id pub-id-type="pmid">10366102</pub-id><pub-id pub-id-type="doi">10.1002/1529-0131(199906)42:6&#x0003c;1101::AID-ANR6&#x0003e;3.0.CO;2-Y</pub-id></citation></ref><ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rees</surname><given-names>LE</given-names></name><name><surname>Wood</surname><given-names>NA</given-names></name><name><surname>Gillespie</surname><given-names>KM</given-names></name><name><surname>Lai</surname><given-names>KN</given-names></name><name><surname>Gaston</surname><given-names>K</given-names></name><name><surname>Mathieson</surname><given-names>PW</given-names></name></person-group><article-title>The interleukin-10 -1082 G/A polymorphism: allele frequency in different populations and functional significance</article-title><source>Cell Mol Life Sci</source><year>2002</year><volume>59</volume><fpage>560</fpage><lpage>569</lpage><pub-id pub-id-type="pmid">11964134</pub-id><pub-id pub-id-type="doi">10.1007/s00018-002-8448-0</pub-id></citation></ref><ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reuss</surname><given-names>E</given-names></name><name><surname>Fimmers</surname><given-names>R</given-names></name><name><surname>Kruger</surname><given-names>A</given-names></name><name><surname>Becker</surname><given-names>C</given-names></name><name><surname>Rittner</surname><given-names>C</given-names></name><name><surname>Hohler</surname><given-names>T</given-names></name></person-group><article-title>Differential regulation of interleukin-10 production by genetic and environmental factors &#x02013; a twin study</article-title><source>Genes Immun</source><year>2002</year><volume>3</volume><fpage>407</fpage><lpage>413</lpage><pub-id pub-id-type="pmid">12424622</pub-id><pub-id pub-id-type="doi">10.1038/sj.gene.6363920</pub-id></citation></ref><ref id="B61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koss</surname><given-names>K</given-names></name><name><surname>Satsangi</surname><given-names>J</given-names></name><name><surname>Fanning</surname><given-names>GC</given-names></name><name><surname>Welsh</surname><given-names>KI</given-names></name><name><surname>Jewell</surname><given-names>DP</given-names></name></person-group><article-title>Cytokine (TNF&#x003b1;, LT &#x003b1; l and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies</article-title><source>Genes Immun</source><year>2000</year><volume>1</volume><fpage>185</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">11196710</pub-id><pub-id pub-id-type="doi">10.1038/sj.gene.6363657</pub-id></citation></ref><ref id="B62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Su&#x000e1;rez</surname><given-names>A</given-names></name><name><surname>Castro</surname><given-names>P</given-names></name><name><surname>Alonso</surname><given-names>R</given-names></name><name><surname>Mozo</surname><given-names>L</given-names></name><name><surname>Guti&#x000e9;rrez</surname><given-names>C</given-names></name></person-group><article-title>Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms</article-title><source>Transplantation</source><year>2003</year><volume>75</volume><fpage>711</fpage><lpage>717</lpage><pub-id pub-id-type="pmid">12640314</pub-id><pub-id pub-id-type="doi">10.1097/01.TP.0000055216.19866.9A</pub-id></citation></ref><ref id="B63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>DM</given-names></name><name><surname>Williams</surname><given-names>DM</given-names></name><name><surname>Sankaran</surname><given-names>D</given-names></name><name><surname>Lazarus</surname><given-names>M</given-names></name><name><surname>Sinnott</surname><given-names>PJ</given-names></name><name><surname>Hutchinson</surname><given-names>IV</given-names></name></person-group><article-title>An investigation of polymorphism in the interleukin-10 gene promoter</article-title><source>Eur J Immunogenet</source><year>1997</year><volume>24</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9043871</pub-id></citation></ref><ref id="B64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yilmaz</surname><given-names>V</given-names></name><name><surname>Yent&#x000fc;r</surname><given-names>SP</given-names></name><name><surname>Saruhan-Direskeneli</surname><given-names>G</given-names></name></person-group><article-title>IL-12 and IL-10 polymorphisms and their effects on cytokine production</article-title><source>Cytokine</source><year>2005</year><volume>30</volume><fpage>188</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">15863393</pub-id><pub-id pub-id-type="doi">10.1016/j.cyto.2005.01.006</pub-id></citation></ref><ref id="B65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huizinga</surname><given-names>TWJ</given-names></name><name><surname>Keijsers</surname><given-names>V</given-names></name><name><surname>Yanni</surname><given-names>G</given-names></name><name><surname>Hall</surname><given-names>M</given-names></name><name><surname>Ramage</surname><given-names>W</given-names></name><name><surname>Lanchbury</surname><given-names>J</given-names></name><name><surname>Pitzalis</surname><given-names>C</given-names></name><name><surname>Drossaers-Bakker</surname><given-names>WK</given-names></name><name><surname>Westendorp</surname><given-names>RGJ</given-names></name><name><surname>Breedveld</surname><given-names>FC</given-names></name><etal></etal></person-group><article-title>Are differences in interleukin 10 production associated with joint damage?</article-title><source>Rheumatology</source><year>2000</year><volume>39</volume><fpage>1180</fpage><lpage>1188</lpage><pub-id pub-id-type="pmid">11085795</pub-id><pub-id pub-id-type="doi">10.1093/rheumatology/39.11.1180</pub-id></citation></ref><ref id="B66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Warl&#x000e9;</surname><given-names>MC</given-names></name><name><surname>Farhan</surname><given-names>A</given-names></name><name><surname>Metselaar</surname><given-names>HJ</given-names></name><name><surname>Hop</surname><given-names>WCJ</given-names></name><name><surname>Perrey</surname><given-names>C</given-names></name><name><surname>Zondervan</surname><given-names>PE</given-names></name><name><surname>Kap</surname><given-names>M</given-names></name><name><surname>Kwekkeboom</surname><given-names>J</given-names></name><name><surname>Ijzermans</surname><given-names>JNM</given-names></name><name><surname>Tilanus</surname><given-names>HW</given-names></name><etal></etal></person-group><article-title>Are cytokine gene polymorphisms related to in vitro cytokine production profiles?</article-title><source>Liver Transpl</source><year>2003</year><volume>9</volume><fpage>170</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">12548511</pub-id><pub-id pub-id-type="doi">10.1053/jlts.2002.50014</pub-id></citation></ref></ref-list></back></article> 